Applied BioCode (6598.TW) Dionica Cijena

Applied BioCode Cijena

TWSE·ZATVORENO
27,75TWD-0,05 (-0,18 %)
Tržište zatvoreno

Revenue has compounded at 27,1% per year over the past 12 years to 475,20 mil. TWD. Applied BioCode's net margin stands at −42,3%, up from −51,6% several years earlier. The stock trades about 44% above its 52-week low.

Cijena dionice Applied BioCode

Volumen
Detalji

Tečaj

Pregled

Dijagram cijene dionica pruža detaljan i dinamičan uvid u performanse Applied BioCode-dionice te prikazuje agregirane cijene na dnevnoj, tjednoj ili mjesečnoj razini. Korisnici mogu mijenjati različite vremenske okvire kako bi pažljivo analizirali povijest dionice i donijeli informirane odluke o investiranju.

Intraday Funkcija

Intraday funkcija pruža podatke u stvarnom vremenu i omogućava investitorima praćenje fluktuacija cijene Applied BioCode-dionice tijekom trgovačkog dana kako bi donosili pravovremene i strateške odluke o ulaganju.

Ukupni povrat i relativna promjena cijene

Pogledajte ukupni povrat Applied BioCode-dionice kako biste procijenili njezinu profitabilnost tijekom vremena. Relativna promjena cijene, temeljena na prvoj dostupnoj cijeni u odabranom vremenskom okviru, pruža uvid u performanse dionice i pomaže u procjeni njezinog potencijala za ulaganje.

Interpretacija i ulaganje

Iskoristite opsežne podatke prikazane na dijagramu cijene dionica za analizu tržišnih trendova, kretanja cijena i potencijalnih povrata od Applied BioCode. Donosite informirane odluke o ulaganju uspoređujući različite vremenske okvire i vrednujući intraday podatke za optimizirano upravljanje portfeljem.

Applied BioCode Povijest cijene dionice
DatumApplied BioCode Cijena dionice
13. 08. 2026.27,75 TWD
12. 08. 2026.27,80 TWD
11. 08. 2026.27,65 TWD
10. 08. 2026.28,80 TWD
07. 08. 2026.28,80 TWD
06. 08. 2026.30,15 TWD
05. 08. 2026.31,10 TWD
04. 08. 2026.31,50 TWD
03. 08. 2026.31,00 TWD
31. 07. 2026.30,20 TWD
30. 07. 2026.28,75 TWD
29. 07. 2026.29,85 TWD
28. 07. 2026.29,10 TWD
27. 07. 2026.30,00 TWD
24. 07. 2026.27,70 TWD
23. 07. 2026.28,80 TWD
22. 07. 2026.27,85 TWD
21. 07. 2026.26,65 TWD
20. 07. 2026.26,85 TWD
17. 07. 2026.27,65 TWD
16. 07. 2026.25,20 TWD
15. 07. 2026.26,15 TWD
14. 07. 2026.23,80 TWD
13. 07. 2026.24,80 TWD
10. 07. 2026.22,85 TWD
09. 07. 2026.22,85 TWD
08. 07. 2026.22,75 TWD
07. 07. 2026.22,95 TWD
06. 07. 2026.23,25 TWD
03. 07. 2026.23,05 TWD
02. 07. 2026.22,75 TWD
01. 07. 2026.22,50 TWD
30. 06. 2026.22,85 TWD
29. 06. 2026.22,85 TWD
26. 06. 2026.22,80 TWD
25. 06. 2026.22,90 TWD
24. 06. 2026.23,20 TWD
23. 06. 2026.23,45 TWD
22. 06. 2026.23,75 TWD
18. 06. 2026.24,15 TWD
17. 06. 2026.24,40 TWD
16. 06. 2026.24,40 TWD
15. 06. 2026.25,00 TWD
12. 06. 2026.24,60 TWD
11. 06. 2026.24,50 TWD
10. 06. 2026.24,90 TWD
09. 06. 2026.25,00 TWD
08. 06. 2026.24,50 TWD
05. 06. 2026.24,50 TWD
04. 06. 2026.24,50 TWD
03. 06. 2026.24,10 TWD
02. 06. 2026.24,30 TWD
01. 06. 2026.24,20 TWD
29. 05. 2026.24,75 TWD
28. 05. 2026.24,75 TWD
27. 05. 2026.24,95 TWD
26. 05. 2026.24,85 TWD
25. 05. 2026.24,50 TWD
22. 05. 2026.24,30 TWD
21. 05. 2026.24,30 TWD
20. 05. 2026.24,20 TWD
19. 05. 2026.24,65 TWD
18. 05. 2026.24,50 TWD
15. 05. 2026.24,35 TWD
14. 05. 2026.23,75 TWD
13. 05. 2026.24,15 TWD
12. 05. 2026.23,35 TWD
11. 05. 2026.22,70 TWD
08. 05. 2026.22,50 TWD
07. 05. 2026.22,60 TWD
06. 05. 2026.22,90 TWD
05. 05. 2026.22,55 TWD
04. 05. 2026.22,55 TWD
30. 04. 2026.21,45 TWD
29. 04. 2026.21,95 TWD
28. 04. 2026.21,90 TWD
27. 04. 2026.21,90 TWD
24. 04. 2026.21,95 TWD
23. 04. 2026.21,85 TWD
22. 04. 2026.22,15 TWD
21. 04. 2026.22,25 TWD
20. 04. 2026.22,70 TWD
17. 04. 2026.22,80 TWD
16. 04. 2026.22,90 TWD
15. 04. 2026.22,80 TWD
14. 04. 2026.22,60 TWD
13. 04. 2026.22,60 TWD
10. 04. 2026.22,00 TWD
09. 04. 2026.21,80 TWD
08. 04. 2026.22,80 TWD
07. 04. 2026.22,55 TWD
02. 04. 2026.23,10 TWD
01. 04. 2026.23,40 TWD
31. 03. 2026.22,65 TWD
30. 03. 2026.23,30 TWD
27. 03. 2026.23,35 TWD
26. 03. 2026.23,55 TWD
25. 03. 2026.24,15 TWD
24. 03. 2026.23,65 TWD
23. 03. 2026.24,25 TWD
20. 03. 2026.24,95 TWD
19. 03. 2026.25,00 TWD
18. 03. 2026.24,80 TWD
17. 03. 2026.24,60 TWD
16. 03. 2026.24,80 TWD
13. 03. 2026.25,05 TWD
12. 03. 2026.24,55 TWD
11. 03. 2026.25,30 TWD
10. 03. 2026.23,90 TWD
09. 03. 2026.23,60 TWD
06. 03. 2026.24,65 TWD
05. 03. 2026.24,50 TWD
26. 02. 2026.25,30 TWD
25. 02. 2026.24,55 TWD
24. 02. 2026.24,35 TWD
23. 02. 2026.24,50 TWD
11. 02. 2026.24,05 TWD
10. 02. 2026.24,05 TWD
09. 02. 2026.25,65 TWD
06. 02. 2026.23,35 TWD
05. 02. 2026.24,30 TWD
04. 02. 2026.24,40 TWD
03. 02. 2026.24,10 TWD
02. 02. 2026.23,60 TWD
30. 01. 2026.24,10 TWD
29. 01. 2026.24,05 TWD
28. 01. 2026.24,80 TWD
27. 01. 2026.24,15 TWD
26. 01. 2026.23,95 TWD
23. 01. 2026.23,60 TWD
22. 01. 2026.24,05 TWD
21. 01. 2026.23,45 TWD
20. 01. 2026.23,90 TWD
19. 01. 2026.24,50 TWD
16. 01. 2026.24,45 TWD
15. 01. 2026.24,60 TWD
13. 01. 2026.23,40 TWD
12. 01. 2026.24,25 TWD
09. 01. 2026.23,15 TWD
08. 01. 2026.23,05 TWD
07. 01. 2026.22,30 TWD
06. 01. 2026.22,40 TWD
05. 01. 2026.22,35 TWD
02. 01. 2026.22,00 TWD
31. 12. 2025.22,00 TWD
30. 12. 2025.22,00 TWD
29. 12. 2025.22,30 TWD
26. 12. 2025.22,05 TWD
24. 12. 2025.21,60 TWD
23. 12. 2025.22,00 TWD
22. 12. 2025.22,10 TWD
19. 12. 2025.21,50 TWD
18. 12. 2025.21,25 TWD
17. 12. 2025.21,10 TWD
16. 12. 2025.21,10 TWD
15. 12. 2025.21,25 TWD
12. 12. 2025.21,10 TWD
11. 12. 2025.21,40 TWD
10. 12. 2025.21,45 TWD
09. 12. 2025.21,30 TWD
08. 12. 2025.21,40 TWD
05. 12. 2025.21,55 TWD
04. 12. 2025.21,40 TWD
03. 12. 2025.21,65 TWD
02. 12. 2025.21,65 TWD
01. 12. 2025.21,75 TWD
28. 11. 2025.22,10 TWD
27. 11. 2025.21,70 TWD
26. 11. 2025.21,55 TWD
25. 11. 2025.21,35 TWD
24. 11. 2025.21,20 TWD
21. 11. 2025.21,20 TWD
20. 11. 2025.20,95 TWD
19. 11. 2025.20,55 TWD
18. 11. 2025.21,00 TWD
17. 11. 2025.21,00 TWD
14. 11. 2025.21,10 TWD
13. 11. 2025.21,25 TWD
12. 11. 2025.21,30 TWD
11. 11. 2025.21,85 TWD
10. 11. 2025.22,70 TWD
07. 11. 2025.23,10 TWD
06. 11. 2025.22,70 TWD
05. 11. 2025.22,70 TWD
04. 11. 2025.22,65 TWD
03. 11. 2025.22,80 TWD
31. 10. 2025.22,90 TWD
30. 10. 2025.23,00 TWD
29. 10. 2025.22,55 TWD
28. 10. 2025.23,05 TWD
27. 10. 2025.23,00 TWD
23. 10. 2025.23,10 TWD
22. 10. 2025.23,15 TWD
21. 10. 2025.23,00 TWD
20. 10. 2025.23,10 TWD
17. 10. 2025.23,00 TWD
16. 10. 2025.22,95 TWD
15. 10. 2025.22,85 TWD
14. 10. 2025.22,75 TWD
13. 10. 2025.23,00 TWD
09. 10. 2025.23,10 TWD
08. 10. 2025.22,70 TWD
07. 10. 2025.22,95 TWD
03. 10. 2025.22,55 TWD
02. 10. 2025.22,60 TWD
01. 10. 2025.23,30 TWD
30. 09. 2025.23,65 TWD
26. 09. 2025.23,60 TWD
25. 09. 2025.23,00 TWD
24. 09. 2025.22,65 TWD
23. 09. 2025.22,60 TWD
22. 09. 2025.22,45 TWD
19. 09. 2025.22,70 TWD
18. 09. 2025.22,95 TWD
17. 09. 2025.23,05 TWD
16. 09. 2025.23,10 TWD
15. 09. 2025.23,05 TWD
12. 09. 2025.23,15 TWD
11. 09. 2025.23,35 TWD
10. 09. 2025.23,35 TWD
09. 09. 2025.23,25 TWD
08. 09. 2025.21,40 TWD
05. 09. 2025.20,85 TWD
04. 09. 2025.22,00 TWD
03. 09. 2025.20,60 TWD
02. 09. 2025.19,70 TWD
01. 09. 2025.19,35 TWD
29. 08. 2025.19,60 TWD
28. 08. 2025.19,55 TWD
27. 08. 2025.19,55 TWD
26. 08. 2025.19,55 TWD
25. 08. 2025.19,60 TWD
22. 08. 2025.19,35 TWD
21. 08. 2025.19,35 TWD
20. 08. 2025.19,25 TWD
19. 08. 2025.19,30 TWD
18. 08. 2025.19,55 TWD
15. 08. 2025.19,55 TWD
Access this data via the Eulerpool API

Applied BioCode dionica promet, EBIT, dobit

  • 3 godine

  • 5 godina

  • 10 godina

  • 25 godina

  • Max

Prihod
EBIT
Dobit
Details
Date
Prihod
EBIT
Dobit
1. sij 2019.
104,69 mil. TWD
−273,46 mil. TWD
−280,07 mil. TWD
1. sij 2020.
299,02 mil. TWD
−99,16 mil. TWD
−103,50 mil. TWD
1. sij 2021.
319,96 mil. TWD
−162,31 mil. TWD
−165,20 mil. TWD
1. sij 2022.
390,30 mil. TWD
−181,93 mil. TWD
−184,73 mil. TWD
1. sij 2023.
395,17 mil. TWD
−186,70 mil. TWD
−164,20 mil. TWD
1. sij 2024.
343,07 mil. TWD
−277,67 mil. TWD
−260,81 mil. TWD
1. sij 2025.
475,20 mil. TWD
−223,33 mil. TWD
−201,20 mil. TWD
1. sij 2026. (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode Dionice Ključni pokazatelji

Zadnje ažurirano 14. kol 2026. 07:00
 
PRIHODmil. TWD
Rast prihoda%
BRUTO MARGINA%
BRUTO DOHODAKmil. TWD
EBITmil. TWD
EBIT-MARŽA%
DOBITmil. TWD
Rast dobiti%
BROJ DIONICAmil.
20132014201520162017201820192020202120222023202420252026e
26,0015,0023,0011,0026,0037,00104,00299,00319,00390,00395,00343,00475,00
−42,3153,33−52,17136,3642,31181,08187,506,6922,261,28−13,1638,48
7,6913,3326,0936,3630,7743,2450,0064,5559,2560,0067,8559,1854,74
2,002,006,004,008,0016,0052,00193,00189,00234,00268,00203,00260,00260,00
−83,00−162,00−221,00−194,00−263,00−267,00−273,00−99,00−162,00−181,00−186,00−277,00−223,00
−319,23−1.080,00−960,87−1.763,64−1.011,54−721,62−262,50−33,11−50,78−46,41−47,09−80,76−46,95
−208,00−71,00−21,00−135,00−263,00−268,00−280,00−103,00−165,00−184,00−164,00−260,00−201,00
−65,87−70,42542,8694,811,904,48−63,2160,1911,52−10,8758,54−22,69
102,65102,65102,6540,0546,6659,4271,1681,5981,7381,6981,77102,79102,65102,65
Detalji

GuV

Prihod i rast

Prihod tvrtke Applied BioCode i rast prihoda ključni su za razumijevanje financijskog zdravlja i operativne učinkovitosti poduzeća. Stalni porast prihoda ukazuje na sposobnost poduzeća da učinkovito tržišno pozicionira i prodaje svoje proizvode ili usluge, dok postotak rasta prihoda pruža uvid u tempo kojim poduzeće raste tijekom godina.

Bruto marža

Bruto marža ključan je faktor koji pokazuje postotak prihoda iznad troškova proizvodnje. Viša bruto marža ukazuje na učinkovitost poduzeća u kontroli proizvodnih troškova i obećava potencijalnu profitabilnost i financijsku stabilnost.

EBIT i EBIT marža

EBIT (Earnings Before Interest and Taxes) i EBIT marža pružaju duboke uvide u profitabilnost poduzeća, bez utjecaja kamata i poreza. Investitori često ocjenjuju ove metrike kako bi procijenili operativnu učinkovitost i inherentnu profitabilnost poduzeća neovisno o njegovoj financijskoj strukturi i poreznoj okolini.

Dohodak i rast

Neto dohodak i njegov kasniji rast neophodni su za investitore koji žele razumjeti profitabilnost poduzeća. Stalni rast dohotka ističe sposobnost poduzeća da poveća svoju profitabilnost tijekom vremena te odražava operativnu učinkovitost, stratešku konkurentnost i financijsko zdravlje.

Izdane dionice

Izdane dionice odnose se na ukupni broj dionica koje je poduzeće izdalo. To je ključno za izračun važnih pokazatelja poput zarade po dionici (EPS), koji je za investitore od ključne važnosti za procjenu profitabilnosti poduzeća po osnovi po dionici i pruža detaljniji pregled financijskog zdravlja i vrednovanja.

Interpretacija godišnjeg uspoređivanja

Uspoređivanje godišnjih podataka omogućuje investitorima da identificiraju trendove, procijene rast poduzeća i predviđaju potencijalnu buduću izvedbu. Analiza kako se pokazatelji poput prihoda, dohotka i marži mijenjaju iz godine u godinu može pružiti vrijedne uvide u operativnu učinkovitost, konkurentnost i financijsko zdravlje poduzeća.

Očekivanja i prognoze

Investitori često uspoređuju trenutne i prošle financijske podatke s tržišnim očekivanjima. Ta usporedba pomaže u procjeni da li poduzeće Applied BioCode posluje kako se očekivalo, ispod prosjeka ili iznad prosjeka te pruža ključne podatke za investicijske odluke.

Applied BioCode Aktie marže

Applied BioCode analiza marži pokazuje bruto maržu, EBIT maržu, kao i profitnu maržu od Applied BioCode. EBIT marža (EBIT/Promet) pokazuje koliko posto prometa ostaje kao operativni dobitak. Profitna marža pokazuje koliko posto prometa od Applied BioCode ostaje.
  • 3 godine

  • 5 godina

  • 10 godina

  • 25 godina

  • Max

Bruto marža
EBIT marža
Marža dobiti
Details
Date
Bruto marža
EBIT marža
Marža dobiti
1. sij 2019.
50,59 %
−261,20 %
−267,52 %
1. sij 2020.
64,72 %
−33,16 %
−34,61 %
1. sij 2021.
59,18 %
−50,73 %
−51,63 %
1. sij 2022.
60,00 %
−46,61 %
−47,33 %
1. sij 2023.
68,01 %
−47,25 %
−41,55 %
1. sij 2024.
59,46 %
−80,94 %
−76,02 %
1. sij 2025.
54,90 %
−47,00 %
−42,34 %
1. sij 2026. (e)
54,90 %
0,00 %
0,00 %

Applied BioCode dionica prihod, EBIT, dobit po dionici

Applied BioCode-Prihod po dionici time pokazuje koliko prihoda Applied BioCode pada na jednu dionicu u određenom razdoblju. EBIT po dionici pokazuje koliko od operativne dobiti pada na svaku dionicu. Dobit po dionici pokazuje koliko dobiti pada na svaku dionicu.
  • 3 godine

  • 5 godina

  • 10 godina

  • 25 godina

  • Max

Prihod po dionici
EBIT po dionici
Dobit po dionici
Details
Date
Prihod po dionici
EBIT po dionici
Dobit po dionici
1. sij 2019.
1,47 TWD
−3,84 TWD
−3,94 TWD
1. sij 2020.
3,66 TWD
−1,22 TWD
−1,27 TWD
1. sij 2021.
3,91 TWD
−1,99 TWD
−2,02 TWD
1. sij 2022.
4,78 TWD
−2,23 TWD
−2,26 TWD
1. sij 2023.
4,83 TWD
−2,28 TWD
−2,01 TWD
1. sij 2024.
3,34 TWD
−2,70 TWD
−2,54 TWD
1. sij 2025.
4,63 TWD
−2,18 TWD
−1,96 TWD
1. sij 2026. (e)
0,00 TWD
0,00 TWD
0,00 TWD

Dioncia Applied BioCode i analiza dionice

Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice.

Vrednovanje Applied BioCode prema fer vrijednosti

Detalji

Fair Value

Razumijevanje Fair Value

Fair Value dionice pruža uvide u to je li dionica trenutno podcijenjena ili precijenjena. Izračunava se na temelju dobiti, prihoda ili dividende i pruža sveobuhvatan pogled na unutarnju vrijednost dionice.

Fair Value baziran na dobiti

Ovaj se izračunava množenjem dobiti po dionici sa prosječnim P/E omjerom proteklih odabranih godina za izračunavanje prosječne vrijednosti (glättung). Ako je Fair Value viši od trenutne tržišne cijene, to ukazuje na to da je dionica podcijenjena.

Primjer 2022

Fair Value Dobit 2022 = Dobit po dionici 2022 / Prosječni P/E omjer 2019 - 2021 (glättung 3 godine)

Fair Value baziran na prihodima

Izračunava se množenjem prihoda po dionici sa prosječnim omjerom cijene i prihoda proteklih odabranih godina za izračun prosječnih vrijednosti (glättung). Dionica se smatra podcijenjenom ako Fair Value premašuje tekuću cijenu dionice.

Primjer 2022

Fair Value Prihod 2022 = Prihod po dionici 2022 / Prosječni omjer cijene i prihoda 2019 - 2021 (glättung 3 godine)

Fair Value baziran na dividendi

Ova vrijednost se određuje dijeljenjem dividende po dionici s prosječnim prinosom dividende odabranih proteklih godina za izračun prosječnih vrijednosti (glättung). Veći Fair Value u odnosu na tržišnu cijenu signalizira da je dionica podcijenjena.

Primjer 2022

Fair Value Dividenda 2022 = Dividenda po dionici 2022 * Prosječni prinos dividende 2019 - 2021 (glättung 3 godine)

Očekivanja i prognoze

Buduća očekivanja daju potencijalne trajektorije za kretanje cijena dionica i pomažu investitorima u donošenju odluka. Očekivane vrijednosti su prognozirani brojevi Fair Value, uzimajući u obzir trendove rasta ili pada dobiti, prihoda ili dividende.

Usporedna analiza

Usporedba Fair Value, na osnovi dobiti, prihoda i dividendi, pruža sveobuhvatan pregled financijskog zdravlja dionice. Praćenje godišnjih i po-godišnjih varijacija pridonosi razumijevanju stalnosti i pouzdanosti performansi dionice.

Vrednovanje Applied BioCode prema historijskom KGV-u, EBIT-multiplom i KUV-u

Applied BioCode dionica, godišnji prinos

Detalji

Rendita

Razumijevanje grafikona prinosa

Grafikon prinosa pruža sveobuhvatan pregled godišnjeg prinosa za . Podijeljen je u dva dijela - prinos od cijene dionice i prinos od dividendi te pruža uvid u ukupnu učinkovitost i profitabilnost investicije.

Prinos od cijene dionice

Ovaj odjeljak prikazuje godišnji prinos koji proizlazi iz povećanja ili smanjenja cijene dionica . Analiza ovih podataka može pomoći investitorima da razumiju povijesnu izvedbu dionice i predviđaju buduće trendove.

Prinos od dividendi

Prinos od dividendi pokazuje postotak prinosa iz dividendi koje isplaćuje . To je ključni pokazatelj za investitore koji žele ostvariti zaradu pored povećanja vrijednosti dionice.

Donošenje odluka o investiranju

Procjenom i prinosa od cijene dionice i prinosa od dividendi, investitori mogu steći uvid u ukupni povrat investicije. To pomaže u donošenju informiranih odluka i uravnoteženju između strategija ulaganja usmjerenih na rast i prihod.

Applied BioCode Broj dionica

Broj dionica za Applied BioCode u godini 2025 iznosio je 102,65 mil.. To pokazuje na koliko je dionica Applied BioCode podijeljen. Budući da su dioničari vlasnici tvrtke, svaka dionica predstavlja mali udio u vlasništvu tvrtke.
  • 3 godine

  • 5 godina

  • 10 godina

  • 25 godina

  • Max

Broj dionica
Details
Date
Broj dionica
1. sij 2019.
71,16 mil. Dionice
1. sij 2020.
81,59 mil. Dionice
1. sij 2021.
81,73 mil. Dionice
1. sij 2022.
81,69 mil. Dionice
1. sij 2023.
81,77 mil. Dionice
1. sij 2024.
102,79 mil. Dionice
1. sij 2025.
102,65 mil. Dionice
1. sij 2026. (e)
102,65 mil. Dionice
Za Applied BioCode trenutno nema dostupnih cijena i prognoza.

Struktura dioničara Applied BioCode

% Ime
9,73018%
Hsu (Fu-Lung)
Hsu (Fu-Lung)
9,16736%
Maxwell Sensors Incorporation
Maxwell Sensors Incorporation
3,94085%
Eureka BioVenture Partners
Eureka BioVenture Partners
3,06682%
GVT Fund L.P.
GVT Fund L.P.
3,01164%
Celerus Diagnostics
Celerus Diagnostics
2,48303%
Cathay Venture Inc.
Cathay Venture Inc.

Applied BioCode Beneficial Ownership Filings (SEC 13D/G)

Free Float
69,4%
Float Shares
-
Shares Outstanding
-

Applied BioCode Uprava i nadzorni odbor

14 members · 0 % women

Management

ZH

Mr. Zohn-Zen Ho

Founder, Chief Technology Officer, General Manager, Director · od 2008

LH

Mr. Liang-Kai Huang

Chief Financial Officer, Corporate Governance Officer

MA

Mr. Michael Aye

Vice President-Molecular Products

DW

Mr. Donald Wong

Vice President-Productions

YC

Mr. Youning Chen

Deputy General Manager-Taiwan Sub-Subsidiary

GK

Gerald Kowalski

Deputy General Manager-Operation

Board of Directors

JL

Mr. Jia-Long Lee

Chairman of the Board · od 2016

BJ

Mr. Benjamin Jen

Director

LL

Lizzie Lee

Director

WT

Mr. Wen-Jing Tsai

Independent Director

JT

James Tsu

Independent Director

JW

Jim Wu

Independent Director

Često postavljana pitanja o dionici Applied BioCode

The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.

Applied BioCode Corp is primarily active in the biotechnology industry.

The main competitors of Applied BioCode Corp in the market include companies such as Illumina, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, and QIAGEN.

Applied BioCode Corp is a leading biotechnology company specializing in developing and commercializing molecular diagnostic systems. Founded in [insert year], Applied BioCode Corp has a rich history in the field of biotech and has consistently delivered innovative solutions for healthcare professionals. The company is dedicated to improving patient care by revolutionizing diagnostic testing through its proprietary barcoded magnetic bead technology. With a team of highly skilled scientists and engineers, Applied BioCode Corp has gained recognition for its advanced diagnostic platforms that offer high throughput, multiplex capability, and cost-effectiveness. The company continues to expand its product portfolio and collaborate with industry partners to address the evolving needs of the healthcare industry.

Applied BioCode Corp has achieved several significant milestones in its journey. The company has made strides in the development and commercialization of its proprietary Barcoded Magnetic Bead (BMB) technology. This innovative technology offers multiplex testing capabilities, enabling simultaneous analysis of multiple targets, including genes, proteins, and pathogens. Applied BioCode Corp has successfully launched its FDA-cleared BioCode MDx 3000 system, which allows complex diagnostic testing with high precision and speed. Additionally, the company has secured strategic partnerships and collaborations with major healthcare institutions, facilitating the adoption of its BMB technology. Through these achievements, Applied BioCode Corp has established itself as a leader in the field of molecular diagnostics.

Applied BioCode Corp is primarily present in the United States, particularly in the state of California.

Applied BioCode Corp is a prominent biotechnology company that values innovation, integrity, and excellence. With a strong corporate philosophy, Applied BioCode Corp focuses on developing cutting-edge technologies and solutions to revolutionize diagnostics and improve patient care. By merging the fields of molecular diagnostics and multiplex biomarker detection, the company aims to address unmet clinical needs. Applied BioCode Corp is committed to providing accurate and efficient diagnostic products that empower healthcare professionals and ultimately enhance patient outcomes. With its forward-thinking approach and commitment to quality, Applied BioCode Corp strives to contribute to the advancement of healthcare and improve global health outcomes.

9 analysts currently rate the Applied BioCode stock: 0 recommend buying, 3 holding and 6 selling.

Converted at the current exchange rate, the Applied BioCode share trades at 0,75 EUR (27,75 TWD).

Applied BioCode Corp is a leading company in the field of molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable complex biochemical analysis with high accuracy, reliability, and throughput capacity. The business model of Applied BioCode Corp is based on the development and commercialization of diagnostic systems and products for food and water analysis, clinical diagnostics, and research. The company offers innovative solutions to meet the needs of customers in various industries. Applied BioCode Corp's main division is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal tract infections by simultaneously analyzing multiple samples for different bacteria, viruses, and parasites. Another product of the company is the BioCode Respiratory Pathogen Panel (RPP) system, which enables rapid and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP provides an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also produces labeling products such as BioCode screening platforms to enable customers to accurately and timely identify pathogens. The company also offers a wide range of sampling methods and accessories to meet the requirements of diverse customers and applications. Applied BioCode Corp's products are distributed worldwide and are used in various industries, such as food and water analysis, clinical diagnostics, and research. The company focuses on offering innovative solutions to its customers to help meet their needs in terms of analysis, diagnosis, and results. Applied BioCode Corp also operates partnerships and collaborations with other companies to introduce and further develop its systems and products in new areas. The company is constantly striving to improve the quality and accuracy of its products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a company that specializes in the development and commercialization of innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. It offers its customers accurate and reliable solutions to meet their requirements and enhance their efficiency. With an advanced product portfolio, global trade partners, and a dedicated team of professionals, Applied BioCode Corp is undoubtedly one of the leading companies in the field of molecular diagnostics. Applied BioCode Corp is a leading company specializing in molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable highly accurate, reliable, and high-throughput complex biochemical analyses. Their business model focuses on developing and marketing diagnostic systems and products for food and water analysis, clinical diagnostics, and research. They offer innovative solutions to meet the needs of customers in various industries. One of their main divisions is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal infections by simultaneously analyzing multiple samples for various bacteria, viruses, and parasites. Another product is the BioCode Respiratory Pathogen Panel (RPP) system, providing fast and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP offers an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also manufactures labeling products such as BioCode screening platforms, allowing for precise and timely identification of pathogens. They also offer a wide range of sampling methods and accessories to fulfill the requirements of different customers and applications. Their products are distributed worldwide and utilized in various industries including food and water analysis, clinical diagnostics, and research. The company focuses on providing customers with innovative solutions to fulfill their analytical, diagnostic, and result-related needs. They also engage in partnerships and collaborations with other companies to introduce and advance their systems and products in new areas. Applied BioCode Corp is committed to continuously improving the quality and accuracy of their products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a specialized company that develops and markets innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. Their accurate and reliable solutions help customers meet their requirements and increase efficiency. With their advanced product portfolio, global trade partnerships, and dedicated professional team, Applied BioCode Corp is a leading company in the field of molecular diagnostics.

Prihod za Applied BioCode trenutno se ne može izračunati.

Dobit za Applied BioCode trenutno se ne može izračunati.

KGV se za Applied BioCode trenutno ne može izračunati.

KUV se za Applied BioCode trenutno ne može izračunati.

Eulpool Quality Score za Applied BioCode je 4/10.

ISIN od Applied BioCode je KYG0488D1051. ISIN (International Securities Identification Number) je globalno jedinstvena identifikacija za vrijednosne papire.

Ticker od Applied BioCode je 6598.TW. Simbol tickera koristi se za trgovanje dionicama Applied BioCode na burzi.

Applied BioCode je isplaćivao dividende svake godine u proteklih 0 godina.

Applied BioCode je dodijeljen sektoru 'Zdravstvo'.

Dividende od Applied BioCode distribuiraju se u TWD.